Kalaris Therapeutics Stock (NASDAQ:KLRS)
Previous Close
$4.86
52W Range
$2.14 - $24.15
50D Avg
$4.61
200D Avg
$5.65
Market Cap
$93.51M
Avg Vol (3M)
$330.42K
Beta
-
Div Yield
-
KLRS Company Profile
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
KLRS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| WHWK | Whitehawk Therapeutics Inc |
| QNCX | Quince Therapeutics, Inc. |
| SPRB | Spruce Biosciences, Inc. |
| GUTS | Fractyl Health, Inc. Common Stock |
| ORMP | Oramed Pharmaceuticals Inc. |
| ALXO | ALX Oncology Holdings Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| CNTB | Connect Biopharma Holdings Limited |
| ADVM | Adverum Biotechnologies, Inc. |
| STTK | Shattuck Labs, Inc. |